Exact Sciences: Business Model, SWOT Analysis, and Competitors 2026

Exact Sciences Corporation stands as a leading company in Healthcare. Generating $3.25 billion in annual revenue (growing 23.1% year-over-year) and carrying a market capitalization of $19.72 billion, the company has cemented its position as a foundational player in the global Diagnostics & Research landscape. Under the leadership of its leadership team, Exact Sciences Corporation continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Exact Sciences Corporation's business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Exact Sciences Corporation as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Exact Sciences Corporation's position in the Diagnostics & Research market today.

What You Will Learn

1. How Exact Sciences Corporation generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Exact Sciences Corporation's competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Exact Sciences Corporation's main competitors are and how the company compares on key financial metrics
4. Exact Sciences Corporation's key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Exact Sciences Corporation's strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $3.25 billion annual revenue (TTM), +23.1% YoY
• Market Cap: $19.72 billion — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 69.7%, operating margin -9.3%, net margin -6.4%
• Free Cash Flow: $281.87 million
• Return on Equity: -8.7% — reflects current investment phase
• Employees: 7,100 worldwide

Who Owns Exact Sciences Corporation?

Exact Sciences Corporation is publicly traded on the NASDAQ under the ticker symbol EXAS. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Exact Sciences Corporation are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Exact Sciences Corporation has approximately 191 million shares outstanding, with float shares of 0 million — the freely tradeable portion. The stock trades at $103.32 per share as of early 2026.

Exact Sciences Corporation's Mission Statement

Exact Sciences Corporation's strategic mission is aligned with its core business activities in the Diagnostics & Research sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Exact Sciences Corporation's most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Exact Sciences Corporation, the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Exact Sciences Corporation's strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Exact Sciences Corporation Make Money?

As of 2026, Exact Sciences Corporation generates $3.25 billion in annual revenue (growing 23.1% year-over-year), with a 69.7% gross margin and -9.3% operating margin. Market capitalization stands at $19.72 billion. Here is how the company generates its revenue:

As of 2026, Exact Sciences Corporation generates $3.25 billion in annual revenue (growing 23.1% year-over-year), with a 69.7% gross margin and -9.3% operating margin. Market capitalization stands at $19.72 billion. Here is how the company generates its revenue:

Introduction

Exact Sciences Corporation is a leading molecular diagnostics company that specializes in the early detection and prevention of cancer. With a focus on developing innovative screening tests, the company has experienced significant growth in recent years. In this section, we will explore the various ways in which Exact Sciences Corporation generates revenue.

Sales of Cologuard

One of the primary sources of revenue for Exact Sciences Corporation is the sales of their flagship product, Cologuard. Cologuard is a non-invasive, stool-based DNA test that screens for colorectal cancer and precancerous polyps. It is the only FDA-approved, non-invasive test of its kind, providing patients with a convenient and accurate alternative to traditional colonoscopies.

Exact Sciences Corporation markets and sells Cologuard directly to healthcare providers, including primary care physicians and gastroenterologists. The company has built a robust sales force that educates healthcare professionals about the benefits of Cologuard and promotes its adoption as a routine screening tool. The sales of Cologuard have been a major driver of revenue for Exact Sciences Corporation, contributing to its financial success.

Revenues from Laboratory Services

In addition to the sales of Cologuard, Exact Sciences Corporation generates revenue through laboratory services. Once a patient's Cologuard sample is collected, it is shipped to Exact Sciences Corporation's state-of-the-art laboratory for analysis. The company's laboratory services include processing and analyzing the samples, as well as generating detailed test reports for healthcare providers.

Exact Sciences Corporation charges healthcare providers for these laboratory services, which include the costs associated with the processing, analysis, and reporting of each Cologuard test. This revenue stream is essential to the company's financial model, as it provides a recurring source of income from the ongoing demand for Cologuard testing.

Collaborations and Partnerships

Exact Sciences Corporation also generates revenue through collaborations and partnerships with other companies in the healthcare industry. These collaborations may involve joint

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review Exact Sciences Corporation's latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

Exact Sciences Corporation Business Model Canvas

The Business Model Canvas framework provides a structured view of how Exact Sciences Corporation creates, delivers, and captures value.

Key Partners: Exact Sciences Corporation's key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Diagnostics & Research sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Exact Sciences Corporation's most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Exact Sciences Corporation's critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (7,100 employees), proprietary technology, and financial resources ($964.71M in cash).

Value Propositions: Exact Sciences Corporation delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Diagnostics & Research market.

Customer Relationships: Exact Sciences Corporation maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Exact Sciences Corporation reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Exact Sciences Corporation serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Exact Sciences Corporation's major costs include cost of goods sold (30.3% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 109.3% of revenue.

Revenue Streams: Exact Sciences Corporation generates revenue through its core product and service offerings.

Exact Sciences Corporation Competitors

Exact Sciences Corporation competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Diagnostics & Research segment of the Healthcare sector.

Exact Sciences Corporation SWOT Analysis

A SWOT analysis examines Exact Sciences Corporation's internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Exact Sciences Corporation's gross margin of 69.7% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -9.3% demonstrates disciplined cost management even at scale.
• Revenue Growth: Revenue grew 23.1% year-over-year to $3.25B, indicating strong demand for Exact Sciences Corporation's products and services and outperformance relative to many industry peers.

Weaknesses

• High Financial Leverage: With a debt-to-equity ratio of 105.6, Exact Sciences Corporation carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increases vulnerability to rising interest rates.

Opportunities

• Total Addressable Market: Exact Sciences Corporation operates in the Diagnostics & Research segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Exact Sciences Corporation's products and services.
• Strategic Acquisitions: With $964.71M in cash and strong free cash flow generation, Exact Sciences Corporation is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Exact Sciences Corporation's revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Exact Sciences Corporation's business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Exact Sciences Corporation enters 2026 as a leading company in Healthcare, backed by $3.25 billion in annual revenue and a -6.4% net profit margin. The company's 69.7% gross margins and $281.87 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Exact Sciences Corporation's core markets.

For investors and analysts, Exact Sciences Corporation represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Exact Sciences, SEC EDGAR – Exact Sciences Filings, and Exact Sciences's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What does Exact Sciences Corporation do?

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Test

2. How much revenue does Exact Sciences Corporation make?

Exact Sciences Corporation generated $3.25 billion in annual revenue (TTM), with 23.1% year-over-year growth.

3. What is Exact Sciences Corporation's market cap?

Exact Sciences Corporation's market capitalization is approximately $19.72 billion as of early 2026.

4. Is Exact Sciences Corporation profitable?

Exact Sciences Corporation has faced profitability challenges recently. Investors should review the latest quarterly earnings reports.

5. Who are Exact Sciences Corporation's competitors?

Exact Sciences Corporation competes in the Diagnostics & Research sector against companies including Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE).

6. Does Exact Sciences Corporation pay dividends?

Exact Sciences Corporation does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.

7. What is Exact Sciences Corporation's stock ticker?

Exact Sciences Corporation trades on the NASDAQ under the ticker symbol EXAS.

8. What is Exact Sciences Corporation's P/E ratio?

Valuation multiples for Exact Sciences Corporation can be found on major financial platforms such as Yahoo Finance, Bloomberg Terminal, or the company's latest annual report filing.

9. How many employees does Exact Sciences Corporation have?

Exact Sciences Corporation employs approximately 7,100 people worldwide as of the most recent disclosure.

10. What is Exact Sciences Corporation's competitive advantage?

Exact Sciences Corporation's competitive advantages include its established brand, scale in Diagnostics & Research, and track record of execution in the Healthcare sector.